Valuation: TAUNS Laboratories,Inc.

Market Cap 51.59B 318M 278M 256M 236M 445M 30.6B 455M 3.06B 1.2B 14.99B 1.19B 1.17B P/E 2025
8.67x
P/E 2026 * 9.73x
Enterprise Value 58.42B 360M 314M 290M 267M 504M 34.65B 515M 3.47B 1.36B 16.97B 1.35B 1.32B EV / Sales 2025
3.23x
EV / Sales 2026 * 4.04x
Free-Float
29.79%
Yield 2025
5.2%
Yield 2026 * 7.29%
1 day-0.82%
1 week+3.20%
Current month+2.54%
1 month-0.62%
3 months-3.20%
6 months-6.92%
Current year-4.91%
1 week 467
Extreme 467
493
1 month 463
Extreme 463
493
Current year 463
Extreme 463
568
1 year 463
Extreme 463
603
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 01/05/2014
Director of Finance/CFO 66 01/11/2018
Corporate Officer/Principal 39 01/07/2022
Director TitleAgeSince
Director/Board Member 62 01/09/2020
Director/Board Member 53 01/04/2016
Director/Board Member 39 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%+3.20%-7.46% - 318M
-3.66%-6.34%+225.06%+297.63% 20.67B
-0.62%+2.40%-38.72%-22.74% 9.85B
-1.32%+0.65%+48.24%+24.90% 7B
-1.83%+1.92%+268.89%-27.23% 5.55B
+3.43%+7.18%-14.36%-20.83% 5.23B
-8.46%+23.30%+84.85%+105.62% 4.9B
-3.67%-6.92%-43.87% - 4.66B
+1.01%+0.78%-21.33%-25.03% 4.2B
+1.21%+5.98%-14.81%-39.11% 2.72B
Average -1.55%+3.58%+48.65%+36.65% 6.51B
Weighted average by Cap. -2.21%+2.23%+93.76%+102.23%

Financials

2025 2026 *
Net sales 19.06B 117M 103M 94.67M 87.26M 164M 11.31B 168M 1.13B 445M 5.54B 441M 431M 14.76B 90.88M 79.42M 73.29M 67.55M 127M 8.75B 130M 876M 345M 4.29B 341M 334M
Net income 6.5B 40.03M 34.98M 32.28M 29.76M 56.08M 3.86B 57.33M 386M 152M 1.89B 150M 147M 5.2B 32.04M 28M 25.83M 23.81M 44.88M 3.09B 45.88M 309M 121M 1.51B 120M 118M
Net Debt 6.83B 42.06M 36.76M 33.92M 31.26M 58.93M 4.05B 60.24M 405M 159M 1.98B 158M 154M 7.99B 49.24M 43.03M 39.7M 36.6M 68.98M 4.74B 70.51M 475M 187M 2.32B 185M 181M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
17/07/26 JP¥484.00 -0.82% 329,000
16/07/26 JP¥488.00 +4.50% 871,200
15/07/26 JP¥467.00 -0.21% 132,400
14/07/26 JP¥468.00 +0.43% 197,300
13/07/26 JP¥466.00 -0.64% 226,600
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
484.00JPY
Average target price
420.00JPY
Spread / Average Target
-13.22%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock